ClinicalTrials.gg
CompletedNCT06368440Updated Oct 24, 2025

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

A Phase 1 interventional study of AZD6793 and AZD6793 in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
152nd of 194
39 · median 137
Started
2024
with 16 others
Phase 1
42 of 284
none open now
Registered
259th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 152nd largest by enrollment of the 194 interventional ones that give a count, is one of 17 that started in 2024, is one of 42 in phase 1, and was the 259th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.

Read the detailed description

This study will be conducted to assess the safety, tolerability, and PK of oral AZD6793 suspension following single (Part 1) and multiple (Part 2) administrations in healthy Japanese and Chinese participants performed at a single Clinical Unit.

Part 1 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2).
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 until at least 72 hours after study intervention administration.
  • A Follow-up Visit within 6 ± 1 days after the study intervention administration.

Part 2 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2).
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 (the day before first study intervention administration [Day 1]) until Day 10.
  • A Follow-up Visit within 6 ± 1 days after the last study intervention administration.

Participants will be randomized to receive AZD6793 and placebo in both Part 1 and Part 2.

Participants who enrolled in Part 1 will be excluded from participation in Part 2 of the study.

03

Conditions studied

  • Healthy Participants

Keywords

  • Chronic obstructive pulmonary disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. For Japanese participants only:

    1. Participant was born in Japan
    2. Participant has 2 Japanese biological parents and 4 Japanese grandparents as confirmed by the interview.
    3. Participant did not live outside of Japan for more than 10 years at the time of the Screening Visit.
  2. For Chinese participants only:

    1. Participant was born in China (including Hong Kong, Macau, and Taiwan)
    2. Participant has 2 Chinese biological parents and 4 Chinese grandparents as confirmed by the interview.
    3. Participant did not live outside of greater China for more than 10 years at the time of the Screening Visit.
  3. All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  4. Females of must not be lactating and if heterosexually active must agree to use an approved method of highly effective ,
  5. Have a between 18 and 30 kilograms per meter square (kg/m2) inclusive and weigh at least 45 kilograms (kg), at the Screening Visit.
  6. Females of non-childbearing potential must be confirmed at the screening Visit by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (but not tubal ligation).

Main Exclusion Criteria:

1. History of any disease or disorder or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

3. Diagnosis or history of immunodeficiency or increased susceptibility to severe infection, or a clinically significant infection within 4 weeks of the Screening Visit.

4. Any positive result on screening for serum surface antigen, hepatitis B core antibody, or .

5. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD6793.

6. Plasma donation within one month of the Screening Visit or any blood donation/blood loss greater than (>) 500 milliliter (mL) during the 3 months prior to the Screening Visit.

7. Participants who have previously received AZD6793. 8. Positive or indeterminate QuantiFERON® TB test at Screening Visit. 9. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months prior to the Screening Visit.

10. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the Investigator.

11. Positive screen for drugs of abuse, or alcohol or cotinine at the Screening Visit or admission to the Clinical Unit (Day -1).

12. Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) defined as the regular consumption of more than 500 mg of caffeine per day (eg, > 5 cups of coffee [one cup \~100 mg caffeine]; one cup of tea \~30 mg caffeine).

13. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1 AZD6793

    6 Healthy Japanese participants will receive single dose of AZD6793 dose 1 and 2 healthy Japanese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 1: Cohort 2 AZD6793

    6 Healthy Japanese participants will receive single dose of AZD6793 dose 2 and 2 healthy Japanese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 1: Cohort 3 AZD6793

    6 Healthy Chinese participants will receive single dose of AZD6793 dose 1 and 2 healthy Chinese participants will receive matching placebo to AZD6793 as oral suspension on Day 1.

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 2: Cohort 1 AZD6793

    6 Japanese participants will receive single dose of AZD6793 and 2 participants will receive matching placebo on Day 1. After a washout of at least 48 hours, participants will receive AZD6793 or placebo once daily from Day 3 to Day 8.

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 2: Cohort 2 AZD6793

    6 Chinese participants will receive single dose of AZD6793 and 2 participants will receive matching placebo on Day 1. After a washout of at least 48 hours, participants will receive AZD6793 or placebo once daily from Day 3 to Day 8.

    Drug: AZD6793 · Drug: Placebo

Interventions

  • Participants will receive AZD6793 single dose as oral suspension.

  • Participants will receive AZD6793 multiple doses daily as oral suspension.

  • DrugPlacebo

    Participants will receive matching doses of placebo as oral suspension.

06

What researchers measure

Primary outcomes

  1. Part 1 (SAD): Number of Participants with Adverse Events

    To assess the safety and tolerability of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: From Day 1 up to Follow up visit (Day 7±1)

  2. Part 2 (MAD): Number of Participants with Adverse Events

    To assess the safety and tolerability of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: From Day 1 up to Follow up visit (Day 14±1)

Secondary outcomes

  1. Part 1 (SAD) : Maximum Observed Plasma Drug Concentration

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  2. Part 1 (SAD): Time to Reach Peak Concentration (tmax)

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  3. Part 1 (SAD): Terminal Rate Constant, Estimated by Log-Linear Least Squares Regression of the Terminal Part of The Concentration-Time Curve (λz)

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  4. Part 1 (SAD): Half-life Associated with Terminal Slope of a Semi-Logarithmic Concentration-Time Curve (t1/2λz)

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  5. Part 1 (SAD): Partial Area Under the Plasma Concentration Time Curve from Time Zero to Time 12 (AUC[0-12])

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  6. Part 1 (SAD): Partial Area Under the Plasma Concentration Time Curve from Time Zero to Time 24 (AUC[0-24])

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  7. Part 1 (SAD): Area Under the Plasma Concentration Curve from Time Zero to the Last Quantifiable Concentration (AUClast)

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  8. Part 1 (SAD): Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf)

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  9. Part 1 (SAD): Apparent Total Body Clearance of Drug from Plasma After Extravascular Administration (CL/F)

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  10. Part 1 (SAD): Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Vz/F)

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  11. Part 1 (SAD): Dose Normalized AUClast

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  12. Part 1 (SAD): Dose Normalized AUCinf

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  13. Part 1 (SAD): Dose Normalized Cmax

    To characterize PK of AZD6793 following oral administration of single ascending doses in healthy Japanese participants and a single dose in healthy Chinese participants.

    Time frame: Day 1 to Day 3

  14. Part 2 (MAD): Maximum Observed Plasma Drug Concentration (Cmax)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  15. Part 2 (MAD) : Concentration at the End of The Dosing Interval (Ctrough)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  16. Part 2 (MAD): Temporal Change Parameter (TCP)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  17. Part 2 (MAD): Time to Reach Peak Concentration (tmax)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  18. Part 2 (MAD): Terminal Rate Constant, Estimated by Log-Linear Least Squares Regression of the Terminal Part of The Concentration-Time Curve (λz)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  19. Part 2 (MAD): Half-life Associated with Terminal Slope of a Semi-Logarithmic Concentration-Time Curve (t1/2λz)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  20. Part 2 (MAD): Partial Area Under the Plasma Concentration Time Curve from Time Zero to Time 24 (AUC[0-24])

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  21. Part 2 (MAD): Area Under the Plasma Concentration Curve from Time Zero to the Last Quantifiable Concentration (AUClast)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  22. Part 2 (MAD): Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  23. Part 2 (MAD): Area Under Plasma Concentration-Time Curve in The Dosing Interval Tau (AUCtau)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  24. Part 2 (MAD): Apparent Total Body Clearance of Drug from Plasma After Extravascular Administration (CL/F)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  25. Part 2 (MAD): Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Vz/F)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  26. Part 2 (MAD): Dose Normalized AUClast

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  27. Part 2 (MAD): Dose Normalized AUCtau

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  28. Part 2 (MAD): Dose Normalized Cmax

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  29. Part 2 (MAD): Ratio of the Area Under the Curve (Rac AUC)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  30. Part 2 (MAD): Accumulation Ratio Based on Cmax (Rac Cmax)

    To characterize PK of AZD6793 following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Day 1 to Day 10

  31. Part 2 (MAD): Amount of Unchanged Drug Excreted into Urine from Time t1 to Time t2 (Ae[t1-t2])

    To characterize PK of AZD6793 in urine following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Days 1, 2, and 8

  32. Part 2 (MAD): Cumulative Amount of Unchanged Drug Excreted into Urine (Aeinf)

    To characterize PK of AZD6793 in urine following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Days 1, 2, and 8

  33. Part 2 (MAD): Renal Clearance (CLR)

    To characterize PK of AZD6793 in urine following oral administration of multiple doses in healthy Japanese and Chinese participants.

    Time frame: Days 1, 2, and 8

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Dec 2024, 7 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 7 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 16, 2024
StartActual
May 15, 2024
Primary completionActual
Dec 23, 2024
CompletionActual
Dec 23, 2024
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06368440
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
May 15, 2024
Primary completion
Dec 23, 2024
Completion
Dec 23, 2024
Last update
Oct 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6793

Start the discussion